🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

David Berz

Los Angeles Clinical Trials

ORCID: 0000-0001-8368-4601

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma”.

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0974

N/A

1.3DataRank · unranked

44 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v1

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v2

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more